| Stage | GME | % of rev | CME | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $790M | 100.00% | $1.7B | 100.00% | CME ×2.20 |
| Gross profit | $345M | 43.66% | $1.5B | 86.51% | CME +42.9pp |
| Operating income | $160M | 20.27% | $1.1B | 65.70% | CME +45.4pp |
| Pre-tax income | $420M | 53.18% | $1.4B | 77.98% | CME +24.8pp |
| Net income | $299M | 37.80% | $1.0B | 59.68% | CME +21.9pp |
| Stage | GME | CME | Gap · A − B |
|---|---|---|---|
| Revenue | $790M100.00% | $1.7B100.00% | CME ×2.20 |
| Gross profit | 43.66%$345M | 86.51%$1.5B | CME +42.9pp |
| Operating income | 20.27%$160M | 65.70%$1.1B | CME +45.4pp |
| Pre-tax income | 53.18%$420M | 77.98%$1.4B | CME +24.8pp |
| Net income |
| 37.80%$299M |
| 59.68%$1.0B |
| CME +21.9pp |
No shared counterparties.